SCHEMBL7186509

SCHEMBL7186509

CCOC(=O)CN(CCNC(=O)OC(C)(C)C)C(=O)Cn1ccc(=O)nc1NCOCc1ccccc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 1/20 0.38
SKP1 P63208 1/20 0.38
SKP2 Q13309 1/20 0.38
SYK P43405 1/20 0.35
IDO1 P14902 1/20 0.35
TPSAB1 Q15661 1/20 0.34
TPSD1 Q9BZJ3 1/20 0.34
TPSG1 Q9NRR2 1/20 0.34
CTSS P25774 2/20 0.34
CTSL P07711 1/20 0.34
CTSB P07858 1/20 0.34
BRD4 O60885 5/20 0.34
AKT1 P31749 1/20 0.33
MAPT P10636 1/20 0.33
SIGMAR1 Q99720 2/20 0.33
PPID Q08752 1/20 0.32
KIF11 P52732 1/20 0.32
F7 P08709 1/20 0.32
BCHE P06276 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202116 0.90 SYK (0.40) CKS1BSKP1SKP2SYKIDO1
SCHEMBL16490057 0.75 SYK (0.49) CKS1BSKP1SKP2SYKIDO1
SCHEMBL14196595 0.75 SYK (0.49) CKS1BSKP1SKP2SYKIDO1
SCHEMBL6046941 0.75 HPGD (0.41) SYKIDO1CTSSCTSLCTSB
SCHEMBL10077228 0.73 SYK (0.36) CKS1BSKP1SKP2SYKMAPT
SCHEMBL3670409 0.73 RAB9A (0.47) CKS1BSKP1SKP2SYKIDO1
SCHEMBL23453049 0.73 TDP1 (0.41) CKS1BSKP1SKP2
SCHEMBL460716 0.73 MAPT (0.36) CKS1BSKP1SKP2SYKBRD4
SCHEMBL7717128 0.72 ABL1 (0.40) CKS1BSKP1SKP2MAPTSIGMAR1
SCHEMBL432254 0.72 CCNE2 (0.40) BRD4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105286-A1 Linked peptide nucleic acids EGHOLM MICHAEL (US) 2003-06-05 US disclosed
US-6451968-B1 HOOGSTEEN TYPE BASE PAIRING IN TRIPLEX MOTIF; DIAGNOSIS; HEAT RESISTANCE; DETECTION OF POINT MUTATIONS, RESTRICTION ENZYME SITES, AND TRANSCRIPTION INHIBITION ISIS PHARMACEUTICALS, INC. 2002-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105286-A1 Linked peptide nucleic acids RNGTT, NT5C3B, DPYD CKS1B 1294/4885SKP1 4276/4885SKP2 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.